List of Excipients in Branded Drug MUCUS RELIEF 600 MG

Generic Drugs Containing MUCUS RELIEF 600 MG

Company	Ingredient	NDC	Excipient
Guardian Drug Company	guaifenesin	53041-190	CARBOMER HOMOPOLYMER TYPE
Guardian Drug Company	guaifenesin	53041-190	CELLULOSE, MICROCRYSTALLINE
Guardian Drug Company	guaifenesin	53041-190	HYPROMELLOSE
Guardian Drug Company	guaifenesin	53041-190	POVIDONE K90

What are the Most Frequently-Used Excipients in MUCUS RELIEF 600 MG?

# Of NDCs	Excipient
1	CARBOMER HOMOPOLYMER TYPE
1	CELLULOSE, MICROCRYSTALLINE
1	HYPROMELLOSE
1	POVIDONE K90

Mucus Relief 600 mg Excipient Strategy and Commercial Opportunities

Last updated: August 20, 2026

Mucus Relief 600 mg is generally an over-the-counter extended-release guaifenesin tablet used as an expectorant. Its commercial value depends less on active-ingredient exclusivity than on low-cost manufacture, reliable 12-hour release, tablet swallowability, packaging, and retailer distribution. The core opportunity is a differentiated OTC platform built around guaifenesin extended release, with line extensions for cough suppression, pediatric use, sugar-free dosing, rapid disintegration, and private-label supply.

Exact excipients vary by manufacturer and National Drug Code. The analysis below applies to the standard guaifenesin 600 mg extended-release tablet marketed under the Mucus Relief name.

What is Mucus Relief 600 mg?

Mucus Relief 600 mg is an extended-release oral tablet containing 600 mg of guaifenesin. Guaifenesin is an expectorant that helps loosen phlegm and thin bronchial secretions, allowing mucus to be cleared through coughing.

The standard adult and pediatric dosing framework for extended-release guaifenesin is commonly one 600 mg tablet every 12 hours, subject to the product label and age restrictions. The tablet should generally be swallowed whole with water rather than crushed or chewed because mechanical disruption can alter release performance.

Product profile

Attribute	Product characteristic
Active ingredient	Guaifenesin
Strength	600 mg
Dosage form	Extended-release tablet
Therapeutic category	OTC expectorant
Typical dosing interval	Every 12 hours
Primary consumer need	Relief of chest congestion
Regulatory route	OTC monograph or monograph-compliant labeling
Prescription requirement	None
Principal commercial competitors	Mucinex 600 mg, store-brand guaifenesin ER products
Primary differentiation levers	Price, tablet size, release profile, packaging, combination therapy

Guaifenesin has a long history of OTC use. The commercial product is therefore a formulation and distribution business rather than an active pharmaceutical ingredient exclusivity business.

What excipients are used in a guaifenesin 600 mg extended-release tablet?

The excipient system normally combines a hydrophilic release-control polymer, compression aids, flow agents, lubricants, and a protective film coating. The exact qualitative and quantitative formula depends on the manufacturer.

Typical excipient functions

Excipient class	Typical examples	Primary function
Hydrophilic matrix former	Hypromellose, hydroxypropyl methylcellulose	Controls water penetration and guaifenesin release
Diluent	Microcrystalline cellulose, lactose, dibasic calcium phosphate	Adds tablet bulk and supports compression
Binder	Povidone, pregelatinized starch, hypromellose	Improves granule and tablet strength
Disintegrant	Crospovidone, sodium starch glycolate, croscarmellose sodium	Supports breakup of non-matrix portions
Glidant	Colloidal silicon dioxide	Improves powder flow
Lubricant	Magnesium stearate, stearic acid	Reduces sticking and ejection force
Film former	Hypromellose, polyethylene glycol	Protects the tablet and improves appearance
Opacifier or colorant	Titanium dioxide, iron oxides, approved colorants	Provides visual identification and light protection
Sweetener or flavoring	Product-specific	May improve chewable or liquid formats

The highest-value excipient decision is the release-control system. Guaifenesin is commonly delivered through a hydrophilic matrix in which the polymer hydrates after contact with gastrointestinal fluid. The hydrated layer limits drug diffusion and erosion, supporting twice-daily dosing.

What excipient properties matter most?

Particle size, compressibility, polymer viscosity, moisture content, and lubricant concentration affect manufacturing and dissolution. A formulation can meet the target drug load yet fail commercially if it produces oversized tablets, variable hardness, capping, sticking, or an unstable release profile.

Key development targets include:

• Consistent 600 mg guaifenesin content.
• Robust 12-hour dissolution performance.
• Acceptable tablet dimensions for consumer swallowing.
• Adequate hardness without excessive disintegration delay.
• Low friability during high-speed packaging.
• Stability under heat and humidity.
• Minimal impact from food, storage, and transportation conditions.
• Low variability between manufacturing lots.

Excipients that improve processability can also create tradeoffs. Higher polymer loading may improve release control but increase tablet size. More lubricant may reduce sticking but impair wetting and dissolution. A stronger matrix may reduce dose dumping risk but produce an overly slow release profile.

How should the excipient strategy be designed?

A practical formulation strategy uses a direct-compression or dry-granulation platform when the guaifenesin powder and polymer system provide adequate flow and compactibility. Wet granulation can improve content uniformity and tablet strength but adds processing steps, moisture exposure, and cost.

Preferred formulation architecture

A commercial tablet can be structured around four functional layers:

1. Drug-loading phase: Guaifenesin blended with a diluent and matrix polymer.
2. Compression phase: Binder and flow aid adjusted to support high-speed tableting.
3. Release-control phase: Hypromellose grade and concentration selected to meet dissolution targets.
4. Protection phase: Film coating optimized for appearance, handling, and moisture protection.

The formulation should be evaluated against at least three dissolution risks:

• Early release that undermines 12-hour dosing.
• Excessively slow release that reduces expectorant availability.
• Mechanical dose dumping after tablet damage or altered gastrointestinal conditions.

A bilayer or multiparticulate design could create differentiation, but it would increase manufacturing complexity. For a low-price OTC product, a conventional monolithic matrix tablet is usually more commercially attractive unless the product targets a premium segment.

Which excipients create the strongest commercial differentiation?

Hypromellose and related matrix polymers have the greatest direct influence on dosage performance. They are widely available and generally do not create durable product exclusivity by themselves. Their value lies in formulation execution, process robustness, and regulatory documentation.

Specialty excipient opportunities include:

• Lower-viscosity polymers that reduce tablet size.
• Polymer blends that improve release consistency.
• Co-processed excipients that permit direct compression.
• Low-moisture excipient systems for improved stability.
• Natural or “clean-label” excipient options for consumer marketing.
• Taste-masking systems for chewable or orally disintegrating products.
• Novel coatings that reduce tablet friction and improve swallowability.

A manufacturer should avoid relying on an excipient claim that is easily copied. The stronger commercial position comes from a complete package: validated formulation, scalable process, reliable dissolution, attractive tablet dimensions, and consistent supply.

What FDA regulatory status applies to Mucus Relief 600 mg?

Guaifenesin is regulated as an OTC expectorant under FDA’s OTC drug framework. The applicable regulatory requirements include active ingredient conditions, labeling, dosage, warnings, directions, and manufacturing controls.

The FDA’s OTC expectorant monograph identifies guaifenesin as an active ingredient for temporary relief of cough associated with minor throat and bronchial irritation, when used according to permitted conditions (U.S. Food and Drug Administration, 2020).

FDA compliance priorities

A guaifenesin 600 mg extended-release product must address:

• Active ingredient identity and strength.
• Extended-release performance.
• Labeling and directions for use.
• Age-related warnings.
• Tamper-evident packaging.
• Current good manufacturing practice.
• Stability and expiration dating.
• Drug Facts formatting.
• Manufacturing site and product registration requirements.

The product does not generally depend on a new drug application for basic OTC monograph-compliant marketing. A formulation that departs materially from monograph conditions may require a different FDA pathway, such as an approved application or a monograph order process, depending on the change.

What is the Orange Book status of Mucus Relief 600 mg?

Mucus Relief 600 mg is generally not protected through the Orange Book in the same way as a prescription extended-release product. OTC monograph products do not typically have an Orange Book patent listing that blocks ordinary generic-style competition.

The commercial implications are significant:

• No conventional Hatch-Waxman exclusivity period protects the basic product.
• Paragraph IV certification is generally not the central entry mechanism for a monograph-compliant OTC guaifenesin tablet.
• Competitors can market equivalent OTC products if they satisfy applicable FDA requirements.
• Product-specific patents may exist, but they would need to cover a meaningful formulation, manufacturing process, delivery system, or use rather than guaifenesin itself.

The core 600 mg guaifenesin concept is mature. The active ingredient has no meaningful new-molecule exclusivity. Any patent strategy must focus on formulation architecture or a combination product.

When does Mucus Relief 600 mg lose exclusivity?

Mucus Relief 600 mg has no meaningful remaining active-ingredient exclusivity under the conventional prescription-drug framework. The product is exposed to competition from store brands, national brands, online retailers, and contract manufacturers.

Exclusivity timeline

Protection category	Commercial status
New chemical entity exclusivity	Not applicable
Orphan exclusivity	Not applicable
Pediatric exclusivity	Not generally applicable
Prescription patent term	No central protection for standard guaifenesin
OTC monograph protection	No product-specific exclusivity period
Brand trademark	May remain active if maintained
Formulation patent	Possible but product-specific
Trade secret	Potential protection for process parameters and supplier specifications

The key barriers are operational rather than legal. They include retailer authorization, manufacturing scale, quality records, packaging capacity, supply reliability, and shelf placement.

What patents protect guaifenesin 600 mg formulations?

The basic guaifenesin molecule and standard expectorant use are mature. Patentable subject matter may include:

• Controlled-release matrix systems.
• Bilayer tablets.
• Multiparticulate dosage forms.
• Abuse-resistant or tamper-resistant designs.
• Combination products containing guaifenesin and dextromethorphan.
• Novel coatings or taste-masking systems.
• Low-dose or pediatric delivery systems.
• Manufacturing processes that improve dissolution consistency.
• Specific excipient ratios that produce a defined release profile.

Patent strength depends on claim breadth, enablement, prior art, and the ability to show a technical effect. A claim that merely recites guaifenesin, hypromellose, and a conventional tablet is vulnerable if the same combination is disclosed in earlier pharmaceutical literature or patents.

How strong is the patent estate?

The patent estate for a standard Mucus Relief 600 mg tablet is weak unless the product incorporates a distinctive delivery platform. The most defensible assets would claim:

• A narrow but reproducible dissolution profile.
• A specific polymer architecture.
• A manufacturing process that prevents dose dumping.
• A formulation that materially reduces tablet size.
• A combination product with clinically or commercially meaningful performance.
• A delivery format that solves a recognized consumer problem.

Trade secrets may be more valuable than patents for routine OTC products. Granulation endpoints, compression force, coating parameters, polymer grades, and supplier qualification data can be difficult for competitors to reproduce quickly.

What commercial opportunities exist for Mucus Relief 600 mg?

The largest opportunity is cost-efficient private-label supply. Guaifenesin 600 mg extended-release tablets have broad consumer recognition and can be sold through pharmacies, grocery chains, mass retailers, warehouse clubs, and e-commerce channels.

Priority product extensions

Opportunity	Commercial rationale	Excipient or formulation focus
Store-brand 600 mg ER tablet	Lowest-cost substitution for national brands	Robust direct compression and standard matrix
1200 mg ER tablet	Twice-daily congestion relief at larger strength	Higher drug load and tablet-size management
Guaifenesin plus dextromethorphan	Addresses mucus and cough in one product	Separate release control for each active
Sugar-free liquid	Expands access for consumers avoiding sugar	Solubilization, suspension stability, flavor masking
Dye-free tablet	Appeals to sensitivity-conscious consumers	Coating and visual identification without dyes
Smaller swallowable tablet	Addresses tablet adherence	High-efficiency matrix and compact excipient system
Effervescent or powder format	Faster consumer perception of action	Solubility, moisture protection, taste masking
Pediatric liquid	Expands age-specific use	Suspending agents, sweeteners, preservatives
Dual-pack day/night product	Increases basket size	Combination safety and labeling control

Combination products create the greatest regulatory and technical complexity. Dextromethorphan has different release and labeling considerations, and the formulation must prevent release-rate interference between the two active ingredients.

What is the strongest near-term opportunity?

The strongest near-term opportunity is a retailer-specific private-label platform with multiple packaging configurations:

• 20-count trial package.
• 40- or 60-count household package.
• 100-count value package.
• Twin-pack e-commerce configuration.
• Seasonal respiratory-care display pack.

Packaging economics can materially affect margins. A low-cost bottle with an induction seal may be preferable for value channels, while blister packaging can improve portability and adherence but raises packaging cost.

Which companies are challenging Mucus Relief 600 mg?

Competition comes from two groups:

1. National brands, particularly Mucinex guaifenesin products.
2. Generic and private-label manufacturers supplying pharmacy and retail chains.

The principal competitive factors are retail price, brand recognition, product availability, tablet count, packaging, and perceived efficacy. Since the active ingredient is widely available, supply-chain execution can matter more than patent ownership.

Competitive comparison

Factor	National brand	Store brand	New entrant
Consumer recognition	High	Moderate to low	Low initially
Price	Premium	Low	Can be low
Patent barrier	Usually limited for mature ER product	Limited	Limited
Retail access	Established	Established through retailer	Requires contracting
Formulation differentiation	Possible	Usually limited	Main route to differentiation
Marketing cost	High	Moderate	Potentially high
Margin potential	Brand-dependent	Volume-dependent	Depends on channel

A new entrant should not compete solely on active ingredient price. It should offer a measurable benefit, such as smaller tablets, improved packaging, lower retailer cost, better supply continuity, or a combination product.

What generic launch risks exist for Mucus Relief 600 mg?

Generic launch risk is high because standard guaifenesin tablets have low legal protection and multiple manufacturing sources. The main risks are:

• Retailer price compression.
• Difficulty securing shelf placement.
• Seasonal demand volatility.
• Guaifenesin and excipient supply interruptions.
• Dissolution variability after scale-up.
• Tablet sticking and capping during production.
• Consumer confusion between immediate-release and extended-release products.
• Labeling errors involving age limits or dosing intervals.
• Product recalls caused by packaging or quality defects.

A manufacturer can reduce risk through dual sourcing, validated polymer specifications, reserve packaging capacity, and dissolution testing at development, pilot, and commercial scales.

What manufacturing and intellectual-property barriers matter?

Manufacturing barriers are moderate. The product does not require sterile processing, biologic handling, cold-chain distribution, or complex device assembly. The most important technical barrier is reproducible extended-release performance at commercial scale.

Critical process controls include:

• Blend uniformity.
• Granule moisture.
• Compression force.
• Tablet hardness.
• Tablet weight.
• Coating weight gain.
• Dissolution profile.
• Packaging moisture protection.
• Stability under accelerated conditions.

Geographic coverage is broad because guaifenesin products can be manufactured in conventional solid-dose facilities across the United States, India, China, Europe, and other pharmaceutical production centers. Market entry still depends on FDA-compliant quality systems, facility registration, labeling compliance, and retailer qualification.

How should a company build an excipient-led commercial strategy?

A practical strategy has three stages.

Stage 1: Defend the base product

Use a conventional, low-cost hydrophilic matrix tablet with a stable supply of polymer, diluent, lubricant, and coating materials. Prioritize dissolution consistency and tablet size.

Stage 2: Add consumer-facing differentiation

Develop dye-free, smaller, easy-swallow, value-count, and combination versions. These variants can be positioned for different retail channels without requiring a completely new manufacturing platform.

Stage 3: Create protectable technical assets

Pursue patents only where the formulation produces a measurable technical result. Potential targets include compact high-load matrices, controlled-release combinations, improved moisture stability, and novel multiparticulate systems.

The commercial objective should be a platform, not a single SKU. One validated formulation architecture can support pharmacy, mass retail, grocery, club, and e-commerce products with different counts and packaging.

Key Takeaways

• Mucus Relief 600 mg is generally a guaifenesin extended-release OTC tablet.
• The main formulation challenge is achieving reliable 12-hour release without excessive tablet size.
• Hypromellose or another hydrophilic matrix polymer is usually the central release-control excipient.
• Guaifenesin has no meaningful new-molecule exclusivity, and standard OTC products face high generic and private-label competition.
• The Orange Book and Paragraph IV framework generally have limited relevance to a monograph-compliant OTC product.
• Formulation patents are possible but must claim a genuine technical distinction rather than a routine excipient combination.
• The strongest commercial opportunities are private-label supply, smaller tablets, dye-free products, combination therapy, sugar-free liquids, and multi-count packaging.
• Manufacturing reliability, dissolution control, retailer access, and cost are more important than API patent rights.
• Trade secrets covering processing conditions and supplier specifications may provide greater practical protection than broad formulation patents.

FAQs

Can Mucus Relief 600 mg be reformulated as a smaller tablet?

Yes. A smaller tablet would require higher drug-loading efficiency, optimized particle engineering, and a release-control polymer system that maintains the required dissolution profile at reduced excipient volume.

Is hypromellose necessary for guaifenesin extended release?

No. Other hydrophilic or matrix-forming systems may be used, but the selected excipient must support reproducible release, compression, stability, and regulatory compliance.

Can guaifenesin 600 mg be sold in a chewable format?

Potentially, but a chewable product requires different taste-masking, texture, hardness, and release-control design. A conventional extended-release matrix may not be suitable without modification.

Does a private-label Mucus Relief 600 mg product need a new patent?

No. A monograph-compliant OTC product can generally compete without a new patent. A patent is relevant only if the manufacturer seeks protection for a novel formulation, process, combination, or delivery system.

Which excipient opportunity has the highest commercial value?

A compact, robust extended-release matrix has the strongest broad-market value because it can lower manufacturing cost, improve swallowability, and support multiple retailer-specific products from one formulation platform.

References

1. U.S. Food and Drug Administration. (2020). 21 CFR Part 341: Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use. Electronic Code of Federal Regulations. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-341

2. U.S. Food and Drug Administration. (2024). Drug products marketed in the United States that are not subject to an approved application. FDA OTC drug regulatory resources. https://www.fda.gov/drugs

3. U.S. Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. United States Pharmacopeial Convention.

4. U.S. Food and Drug Administration. (2023). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

5. U.S. Food and Drug Administration. (2023). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm